zliming2004

OC-000459

OC-000459 is a CRTH2 receptor antagonist currently undergoing phase II clinical development at Oxagen for the treatment of allergic rhinitis, mild to moderate persistent asthma and active eosinophilic esophagitis.

OC-000459 - zliming2004 - zliming2004的博客

 

OC-000459 - zliming2004 - zliming2004的博客

 


Patent NumberApplicantTitleConditionSubject MatterWO 2006092579
EP 1856094
JP 2008531668
 Oxagen Ltd.  Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acidOC-000459 - zliming2004 - zliming2004的博客  

Asthma

Autoimmune disease

Dermatitis, atopic

OC-000459 - zliming2004 - zliming2004的博客  Dosage Forms and Compositions
 EP 2697215
CN 103502236
JP 2014507449
WO 2012119841
US 2012282223
US 8703956
US 2014255340
US 8980918
  Oxagen Ltd.   Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acidOC-000459 - zliming2004 - zliming2004的博客  

Asthma

Dermatitis, atopic

Rhinitis, allergic

OC-000459 - zliming2004 - zliming2004的博客  Drug Substances
Polymorphs
 

evelopment Status Summary         Details  OC-000459 - zliming2004 - zliming2004的博客 Phase Organization ConditionPhase IIAtopix TherapeuticsAsthmaPhase IIAtopix TherapeuticsConjunctivitis, allergicPhase IIAtopix TherapeuticsDermatitis, atopicPhase IIAtopix TherapeuticsRhinitis, allergic

评论